EVAX
Price
$2.39
Change
-$0.08 (-3.24%)
Updated
Jul 3 closing price
Capitalization
15.1M
REPL
Price
$9.40
Change
-$0.15 (-1.57%)
Updated
Jul 3 closing price
Capitalization
724.62M
27 days until earnings call
Interact to see
Advertisement

EVAX vs REPL

Header iconEVAX vs REPL Comparison
Open Charts EVAX vs REPLBanner chart's image
Evaxion A/S
Price$2.39
Change-$0.08 (-3.24%)
Volume$43.25K
Capitalization15.1M
Replimune Group
Price$9.40
Change-$0.15 (-1.57%)
Volume$581.09K
Capitalization724.62M
EVAX vs REPL Comparison Chart in %
Loading...
EVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EVAX vs. REPL commentary
Jul 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EVAX is a Hold and REPL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 04, 2025
Stock price -- (EVAX: $2.39 vs. REPL: $9.40)
Brand notoriety: EVAX and REPL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EVAX: 46% vs. REPL: 45%
Market capitalization -- EVAX: $15.1M vs. REPL: $724.62M
EVAX [@Biotechnology] is valued at $15.1M. REPL’s [@Biotechnology] market capitalization is $724.62M. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EVAX’s FA Score shows that 1 FA rating(s) are green whileREPL’s FA Score has 1 green FA rating(s).

  • EVAX’s FA Score: 1 green, 4 red.
  • REPL’s FA Score: 1 green, 4 red.
According to our system of comparison, both EVAX and REPL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EVAX’s TA Score shows that 5 TA indicator(s) are bullish while REPL’s TA Score has 5 bullish TA indicator(s).

  • EVAX’s TA Score: 5 bullish, 3 bearish.
  • REPL’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, EVAX is a better buy in the short-term than REPL.

Price Growth

EVAX (@Biotechnology) experienced а -7.54% price change this week, while REPL (@Biotechnology) price change was -0.63% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

EVAX is expected to report earnings on May 27, 2025.

REPL is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REPL($725M) has a higher market cap than EVAX($15.1M). REPL YTD gains are higher at: -22.378 vs. EVAX (-43.459). EVAX has higher annual earnings (EBITDA): -12.99M vs. REPL (-235.43M). REPL has more cash in the bank: 484M vs. EVAX (17.8M). EVAX has less debt than REPL: EVAX (10.5M) vs REPL (76.2M). EVAX has higher revenues than REPL: EVAX (3.29M) vs REPL (0).
EVAXREPLEVAX / REPL
Capitalization15.1M725M2%
EBITDA-12.99M-235.43M6%
Gain YTD-43.459-22.378194%
P/E RatioN/AN/A-
Revenue3.29M0-
Total Cash17.8M484M4%
Total Debt10.5M76.2M14%
FUNDAMENTALS RATINGS
REPL: Fundamental Ratings
REPL
OUTLOOK RATING
1..100
59
VALUATION
overvalued / fair valued / undervalued
1..100
26
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
55
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
EVAXREPL
RSI
ODDS (%)
Bearish Trend 2 days ago
85%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 10 days ago
82%
Bullish Trend 29 days ago
77%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 4 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
86%
Aroon
ODDS (%)
Bullish Trend 2 days ago
64%
Bullish Trend 2 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
EVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IRLAX75.31N/A
N/A
Voya Russell Large Cap Growth Idx Port A
MRJIX10.94N/A
N/A
Morgan Stanley Multi-Asset Real Return I
BGRIX92.75N/A
N/A
Baron Growth Instl
SGSCX32.28N/A
N/A
DWS Global Small Cap S
BPIRX14.45N/A
N/A
Boston Partners Long/Short Rsrch Instl

EVAX and

Correlation & Price change

A.I.dvisor tells us that EVAX and KURA have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EVAX and KURA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EVAX
1D Price
Change %
EVAX100%
-3.24%
KURA - EVAX
31%
Poorly correlated
+0.86%
LPTX - EVAX
30%
Poorly correlated
+1.18%
CRGX - EVAX
28%
Poorly correlated
+1.36%
REPL - EVAX
26%
Poorly correlated
-1.57%
VNDA - EVAX
26%
Poorly correlated
+1.64%
More

REPL and

Correlation & Price change

A.I.dvisor indicates that over the last year, REPL has been loosely correlated with ELVAF. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if REPL jumps, then ELVAF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REPL
1D Price
Change %
REPL100%
-1.57%
ELVAF - REPL
60%
Loosely correlated
N/A
SNDX - REPL
51%
Loosely correlated
N/A
IDYA - REPL
51%
Loosely correlated
+0.82%
XNCR - REPL
49%
Loosely correlated
+1.45%
CGON - REPL
47%
Loosely correlated
+0.82%
More